Experimental Leukemia Drug Effective In Most Patients Who Don't Benefit From Other Treatments: Trial
Category: WELLNESS
AbbVie is developing the once-daily pill in partnership with Roche Holding AG. In the ongoing study, 72 percent of patients
By Reuters, Reuters, 2013-12-08